BR0207899A - Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente - Google Patents

Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente

Info

Publication number
BR0207899A
BR0207899A BR0207899A BR0207899A BR0207899A BR 0207899 A BR0207899 A BR 0207899A BR 0207899 A BR0207899 A BR 0207899A BR 0207899 A BR0207899 A BR 0207899A BR 0207899 A BR0207899 A BR 0207899A
Authority
BR
Brazil
Prior art keywords
immune response
response against
pharmaceutical product
against papillomavirus
papillomavirus
Prior art date
Application number
BR0207899A
Other languages
English (en)
Inventor
Julian Kingdon Hickling
Terry O' Neil
Rienk Offringa
Sjoerd Van Der Burg
Original Assignee
Xenova Res Ltd
Univ Leiden Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Res Ltd, Univ Leiden Medical Ct filed Critical Xenova Res Ltd
Publication of BR0207899A publication Critical patent/BR0207899A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"IMUNóGENO DE COMBINAçãO PARA ADMINISTRAçãO SEQuENCIAL DOS COMPONENTES PARA EVOCAR UMA RESPOSTA IMUNE CONTRA O PAPILOMAVìRUS, PRODUTO FARMACêUTICO, USO DE UM PRODUTO FARMACêUTICO, E, MéTODO PARA EVOCAR UMA RESPOSTA IMUNE CONTRA O PAPILOMAVìRUS EM UM PACIENTE". A invenção diz respeito a imunógenos e vacinas e a sua preparação e uso. Em particular, a invenção oferece imunógenos de combinação compreendendo um iniciador e um reforçador imunógeno direcionado contra antígenos da proteína do papilomavírus, e seu uso para estimular uma resposta imune contra os papilomavírus, tal como uma resposta imune profilática ou terapêutica contra a infecção por papilomavírus humano (HPV).
BR0207899A 2001-03-07 2002-03-07 Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente BR0207899A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105606A GB0105606D0 (en) 2001-03-07 2001-03-07 Immunogens and vaccines and their preparation and use
PCT/GB2002/000975 WO2002070004A2 (en) 2001-03-07 2002-03-07 Papillomavirus vaccines

Publications (1)

Publication Number Publication Date
BR0207899A true BR0207899A (pt) 2004-10-19

Family

ID=9910150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207899A BR0207899A (pt) 2001-03-07 2002-03-07 Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente

Country Status (6)

Country Link
EP (1) EP1399182A2 (pt)
JP (1) JP2004522789A (pt)
AU (1) AU2002236065A1 (pt)
BR (1) BR0207899A (pt)
GB (1) GB0105606D0 (pt)
WO (1) WO2002070004A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013472A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
JP5106384B2 (ja) * 2005-04-27 2012-12-26 ライデン ユニバーシティ メディカル センター Ｈｐｖ誘導性上皮内腫瘍の治療方法及び治療手段
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
JP6974358B2 (ja) 2016-06-07 2021-12-01 ドイチェス クレブスフォルシュンクスツェントルム Ｈｐｖ ｌ２ペプチドの免疫原性の改善
EP3755369A4 (en) * 2018-02-22 2022-01-19 Turnstone Limited Partnership ONCOLYTIC VIRUSES AS ADJUVANTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells

Also Published As

Publication number Publication date
GB0105606D0 (en) 2001-04-25
WO2002070004A2 (en) 2002-09-12
EP1399182A2 (en) 2004-03-24
WO2002070004A3 (en) 2003-12-31
AU2002236065A1 (en) 2002-09-19
JP2004522789A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
Warger et al. Initiation of adaptive immune responses by transcutaneous immunization
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
Schulze et al. New horizons in the development of novel needle-free immunization strategies to increase vaccination efficacy
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
BR0207899A (pt) Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente
WO2001000231A3 (en) Use of cpg as an adjuvant for malaria vaccine
AU1648102A (en) Immunomodulatory constructs and their uses
Ekström et al. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO2003032917A3 (en) Hookworm vaccine
YU99603A (sh) Geni koji su povezani sa virulencijom parazita laišmanije
CN101347616B (zh) 一种新型安全的jy免疫佐剂系统的组方及其应用
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
IL149184A0 (en) Melanoma vaccine and methods of making and using same
Shah et al. Vaccines in dermatology
WO2005027835A3 (en) Therapeutic immunization of hiv-infected individuals

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired